TomoTherapy: Sparks man first to have cancer tumors treated with region's most advanced radiation technology|
RENO, Nev. (Jan. 27, 2009) – With the introduction of a new cancer radiation service for patients who need a wide range of cancer treatments, Renown Health is pleased to announce that a team of cancer specialists successfully treated its first cases with the new TomoTherapy Hi-Art® System. A total of 10 patients were treated during the system’s first day of operation, which was Thursday, Jan. 22.
Due to the large need of cancer treatment in the area, not only did the hospital set a world record in number of cases, but it also set a record in complexity of care (treating patients with multiple tumors simultaneously).
One patient, Daniel Robbins, 50, of Sparks, Nev. said that it was convenient to have such advanced technology so close to home. “I appreciate that I didn’t have to travel to California for daily treatments,” he said. “The people and doctors in Reno are so qualified. I’ve had great experiences every time I’ve gone to Renown Regional Medical Center.”
Renown Health is the first in the region to offer this advanced cancer technology. The system is designed to expand doctors’ ability to use therapeutic radiation to treat tumors with 3-D imaging and improved precision.
Only two percent of hospitals nation-wide have the technology including major cancer institutes like the Kimmel Cancer Center at Johns Hopkins, Baltimore, Md. and University of Wisconsin Comprehensive Cancer Center, Madison, Wis. Approximately 200 devices exist world-wide.
The treatment for these cancer cases relies on the expertise of radiation oncologists like Eric Rost, MD, medical director of Radiation Oncology at Renown Institute for Cancer. Dr. Rost is a national leader in TomoTherapy programs and radiation treatment techniques for cancer tumors.
He previously presided over one of the first installations of a TomoTherapy Hi-Art® System and has brought his expertise to Renown Health. Prior to his arrival at Renown Institute for Cancer, he was a consultant involved with the building of 10 TomoTherapy programs world-wide including Arizona, England, Florida, Italy, Korea and Spain.
Rost said the new system delivers small beamlets of radiation from every point on a spiral, which provides for exceptional accuracy. “TomoTherapy is not only an evolutionary advancement in radiation delivery, but it also is a revolutionary change in the treatment of all cancers,” he said. “Because it is so precise, clinical outcomes for patients are significantly better than other radiation treatment options. And there are fewer side effects because the healthy tissue around tumors is not affected.”
Unlike traditional radiation therapy equipment, the Hi·Art® system utilizes an on-board computed tomography (CT) scanner. This allows true CT images of a patient’s anatomy to be created with the same equipment used to treat that patient. The system allows for tumors to receive their intended doses of radiation with minimal damage to surrounding healthy tissue, reducing patient side effects.
Patient Benefits of TomoTherapy compared to other radiation options:
Fewer side-effects because less healthy tissue impacted Shorter and more accurate treatments
Most accurate radiation available due to CT scan capability
Ability to treat patients who have been told they could not receive any more therapy
The Hi-Art® System has applications for an assortment of cancer treatments across many disciplines treating cancers throughout the entire body. More specifically, mesothelioma, an asbestos-related cancer of the lining of the lung or the lining of the abdominal cavity, can only be treated with TomoTherapy.
TomoTherapy can treat all solid tumors. It is especially good at treating tumors of the brain and spinal cord and patients who are told they have already had radiation and cannot have anymore. Other treatment applications include skin, lung, GYN (ovarian, cervix, endometrium), breast, bone, head and neck, prostate, pediatric, liver, colon, anal, lymphoma, esophagus, gastric and pancreatic cancers.
How the TomoTherapy Hi·Art® treatment system works:
1. Before each treatment, the patient, lying on the bed, moves through the Hi-Art® machine for a CT scan, called a CTrue image. Images taken verify the shape, size and location of the tumor as well as all critical structures.
2. The CTrue image is compared to the original planning CT image (which may have been taken days before). If necessary, adjustments to the plan and patient set-up are made immediately.
3. The patient then moves through the Hi·Art® treatment system again where radiation is delivered in tens of thousands of beamlets in a helical pattern (360°) around the tumor.
4. Each procedure takes approximately 15 minutes.
“We are constantly looking at cancer treatment options,” said Linda Ferris, Ph.D., vice president of Renown Institute for Cancer. “We added da Vinci last February and TomoTherapy is another amazing new machine in Renown Institute for Cancer’s toolbox to treat cancer. There are other tools out there, but we’ve concluded that this technology is essentially a step above the rest.”
Renown Institute for Cancer has been the region’s first hospital recognized by the American College of Surgeons Commission on Cancer for comprehensive cancer care for more than 22 years. Only 25 percent of hospitals nationwide meet the Commission’s rigorous standards.
Renown Health is the largest hospital in the area conducting clinical trials with the National Cancer Institute. Clinical trials allow patients to be on leading trends in medicine and often times they become involved in that "next big discovery" for cancer treatments.
About TomoTherapy Incorporated
TomoTherapy Incorporated has developed, manufactures and sells the Hi·Art® system, one of the most advanced and versatile radiation therapy systems commercially available for the treatment of a wide variety of cancers. TomoTherapy Incorporated markets the Hi·Art® treatment system to university research centers, hospitals, private and governmental institutions and cancer treatment centers in North America, Europe and Asia.